1) The study found that patients with metastatic patients treated with TIL ACT therapy post anti-CTLA4 exposure had a lower overall response rate and median overall survival. TIL persistence, tumor mutational burden, and recognition of autologous tumors did not significantly impact outcomes. However, reduced infused TIL quantity and shorter treatment response duration were noted in patients previously exposed to anti-CTLA4. The study also identified IL-9 as a predictive factor for a favorable response to TIL ACT therapy. The gene discussed is CTLA4; the disease is neoplasm.